Introduction
'yBut for the miscreant exile who returnedy' Antigone by Sophocles.
Similar to Antigone, myeloproliferative disorder (MPD) stem cells appear to be miscreant products of their environment that leave their home or niche but can return to wreak havoc. By studying hematopoietic cells in the context of their environment, William Dameshek 1 made the prescient observation in 1951 that in MPDs, including polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML) and idiopathic myelofibrosis, bone marrow cells proliferate 'as a unit rather than as single elements'. He also raised the specter of a 'myelostimulatory factor' capable of inducing proliferation of hematopoietic cells exiled to extramedullary sites such as the spleen and liver as well as those resident in or returning to the marrow. 1 Evidence for the clonal derivation of MPDs from a wayward or miscreant hematopoietic stem cell (HSC) came from studies demonstrating the same glucose-6-phosphate dehydrogenase (G6PD) allele in PV erythrocytes, granulocytes and platelets. 2 Similar findings were also reported for ET, MF and CML. [3] [4] [5] Later, phosphoglycerate kinase gene PCR confirmed clonal involvement of the myeloid and erythroid lineages in female PV patients. 6 The discovery of the Philadelphia chromosome in CML in 1960 followed by elucidation of the role of its fusion gene product, BCR-ABL, provided a pathogenetic explanation for the initiation of chronic phase CML as well as a critical molecular therapeutic target. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] These landmark discoveries, together with the finding that chronic phase CML originates from a HSC, 5, 19 fueled research into the genetic and epigenetic events driving aberrant differentiation, self-renewal and survival of stem and progenitor cells in both BCR-ABLpositive and -negative MPDs as well as their capacity to subvert the microenvironment. This review will examine the differences between normal HSC and MPD stem and progenitor cells and current as well as potential future clinical efforts to redirect miscreant MPD stem cells toward a normal developmental path.
BCR-ABL-positive MPD stem cells
In CML and other malignancies, compelling data suggest that a population of cancer stem cells (CSCs) is able to regenerate or self-renew resulting in cancer relapse and therapeutic resistance. 19, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] CSCs have been described in a number of cancers, including acute myelogenous leukemia (AML), 24, 25 breast cancer, 26, 27 brain tumors, 28, 29 colon cancer, 30, 31 pancreatic cancer, 32 melanoma, 33 as well as CML. 19, 34, 35 A number of studies indicate that quiescent CSCs, particularly in CML, are resistant to therapies that target rapidly dividing cells. 20, 21 Research that revealed the relative quiescence and therapeutic resistance of CML stem cells provided a framework for unraveling the molecular underpinnings of cancer at a specific developmental stage. [19] [20] [21] Hence, CML is an important paradigm for understanding malignant stem cell differentiation, self-renewal and survival during both early and advanced phases of disease. 19 Because CML was the first cancer to be associated with a pathognomonic chromosomal translocation called the Philadelphia chromosome (Ph þ ) that juxtaposes the c-abl gene on chromosome 9 and the bcr gene on chromosome 22 as t(9;22)(q34;q11), it has been the most extensively investigated cancer from a molecular standpoint. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 19 The fusion gene product of the Philadelphia chromosome, BCR-ABL, produces a constitutively active protein tyrosine kinase. 9, 10 The malignanttransforming capacity of BCR-ABL was initially documented through its ability to support factor-independent growth of primary bone marrow cells in vitro. The first in vivo CML model involved transplantation of BCR-ABL-transduced mouse bone marrow cells into lethally irradiated syngeneic recipients.
Retroviral overexpression of BCR-ABL was necessary and sufficient to induce a MPD similar to chronic phase CML, but rarely recapitulated blast crisis phase underscoring the complexity of malignant transformation. 11, 14 Nonetheless, transplantation and transgenic mouse models provided the impetus for developing targeted BCR-ABL inhibitor therapy that induces hematologic and cytogenetic remissions in the majority of CML patients. [11] [12] [13] [14] [15] [16] [17] [18] However, the failure of BCR-ABL inhibitor therapy to completely eliminate CML stem cells in chronic phase is compounded by the inevitable progression of CML in advanced stages. [16] [17] [18] [19] [20] [21] In blast crisis and imatinib-resistant CML, the granulocyte-macrophage progenitor (GMP) pool is significantly expanded. 19 Aberrant activation of HSC self-renewal programs, as well as inhibition of differentiation and activation of survival programs at an inappropriate developmental stage, leads to accumulation and survival of the more mature and typically short-lived myeloid progenitors. 19 
CML stem cell differentiation
Aberrant CML stem cell differentiation potential was suggested by the observed increase in megakaryocyte-erythrocyte progenitors in untreated chronic phase. 19 A notable insight into the divisive role of transcription factors in CML stem cell differentiation was gained when a deficiency of a transcription factor, JunB, in a transgenic mouse model led to the development of an MPD with a propensity for myeloid differentiation in which serial transplantation potential existed only at the level of HSC. 36 Moreover, granulocyte-macrophage colony stimulating factor (GM-CSF) GM-CSF-mediated survival and proliferation of the JunB-deficient GMPs was associated with changes in antiapoptotic proteins Bcl-2 and Bcl-xL, as well as cell cycle regulators p16 ink4a and c-Jun. 36 Emerging evidence suggests that a transcriptional repressor Bmi1 that is normally restricted to the stem cell compartment is overexpressed in the aggressive forms of CML that progress to blast crisis (BC) within 3 years and during advanced phases of disease. 37 Notably, stem cell-fate determination by the large family of Hox genes is negatively regulated by Bmi1. 38 Some Hox family members such as HoxA9 and HoxB4 as well as the Hox gene master regulator MLL are better known for leukemogenic potential through enhanced HSC self-renewal and myelopoiesis skewing on upregulation. 39 Downregulation of Hox genes, such as HoxA5 impairs myelopoiesis, suggesting differentiation block at the level of HSC. Although inactivation of HoxA4 and HoxA5 through hypermethylation has been detected in 34% of CD34 þ cells from chronic phase CML, it occurs in 90% of the CD34 þ BC CML patient samples. 39 Moreover, inactivation of HoxA4 and HoxA5 through hypermethylation is associated with a poor prognosis in other myeloid and lymphoid malignancies and may be a marker of more severe disease. 39 CML stem and progenitor cell self-renewal Self-renewal is an essential stem cell property but self-renewal pathway activation has also been increasingly recognized as a hallmark of cancer. Activation of the Wnt/b-catenin pathway, important in HSC self-renewal, was detected in blast crisis CML patient samples by confocal fluorescence microscopic analysis. 19 Additional studies revealed that inappropriate activation of the Wnt signaling pathway in GMPs endowed these cells with self-renewal capacity, normally a property of HSC, as measured by generation of replatable myeloid colonies. Replating efficiency was reduced with axinFa potent inhibitor of b-catenin. 19 Self-renewal capacity is normally absent in GMP, þ cells across the disease spectrum identified several critical differentially expressed genes that function in self-renewal, differentiation, survival and DNA damage response. The Wnt pathway, critical for HSC selfrenewal and interaction with the bone marrow niche, was found to be activated during progression to advanced phase. 40 This study linked the abnormality in the free b-catenin pool to decreased JunB expression through the deregulation of MDFI (Imfa)Fan inhibitor of myogenic basic helix-loop-helix transcription factors. 40 Disruption of differentiation and enhancement of self-renewal in CML progenitor cells may be a critical component of disease progression.
CML stem cell survival
By subverting survival pathways normally active in stem cells, CSCs gain the ability to survive for extended periods of time. Deregulation of programmed cell death or apoptosis allows these cells to propagate even as they detach from the niche and accumulate genetic mutations. Apoptosis is initiated following DNA damage but is disrupted in almost every malignancy. As chemotherapeutic agents commonly act by inducing apoptosis, resistance to apoptosis is frequently associated with chemotherapeutic resistance. In CML, resistance to apoptosis begins with BCR-ABL, and notably, the final consequence of BCR-ABL inhibition with imatinib is induction of apoptosis. 41 CML stem cell resistance to apoptosis [19] [20] [21] involves the aberrant expression of the Bcl-2 family of apoptosis-regulatory proteins including antiapoptotic members such as Bcl-2 and Mcl-1 and proapoptotic members such as Bad and Bim. [42] [43] [44] [45] [46] [47] The antiapoptotic members inhibit mitochondrial release of cytochrome c and subsequent Apaf1 activation resulting in inhibition of caspase 9 activation. Pro-apoptotic members act through diverse mechanisms. Although some inhibit the activity of the antiapoptotic members by heterodimerization through BH-3 domains (Bad and Noxa), others form pores (Bax and Bak) in the mitochondrial membrane. [42] [43] [44] [45] [46] [47] Initiation of CML by BCR-ABL leads to resistance to apoptosis. BCR-ABL expression has many effects on Bcl-2 family protein expression. For instance, BCR-ABL-induced PI3 kinase activation of Akt results in downstream inhibition of BadFa pro-apoptotic protein. 43 In addition, BCR-ABL-induced STAT5 activation leads to increased expression of an antiapoptotic protein, Bcl-xL 46 and Bcl-2 expression is increased in BCR-ABL þ cells. 47 Furthermore, BCR-ABL contributes to apoptosis resistance in a dose-dependent manner and BCR-ABL expression increases with disease progression from chronic phase to blast crisis. [48] [49] [50] [51] [52] [53] [54] [55] Transgenic CML mouse model research showed that targeted BCR-ABL expression in myeloid progenitors led to a chronic MPD, whereas targeted overexpression of Bcl-2, but not Ras or Myc, promoted progression to blast crisis. 56 It is noted that activation of the Wnt/b-catenin pathway leads to increased c-myc expression and ultimately results in upregulation of Bcl-2 SPOTLIGHT family proteins. Moreover, GSK3b, a critical negative regulator of the Wnt signaling pathway, has been shown to regulate the activity of both pro-apoptotic and antiapoptotic Bcl-2 family proteins. GSK3b can activate Bax, a membrane pore-forming Bcl-2 family member, by phosphorylation at serine 163 and can also regulate the stability of Mcl-1, one of the antiapoptotic family members. Inhibition of GSK3b through the induction of glucose metabolism leads to stabilized Mcl-1 and resistance to apoptosis. 57 In addition to the Wnt pathway, key apoptosis proteins are highly regulated by the PI3K/Akt pathway. In response to metabolic, survival and growth signals, PI3K activates Akt, which then acts on a number of downstream targets. Akt directly inhibits Bad and Bax 58 and modulates the activity of transcription factors such as those from the NF-kB and FoxO families. NF-kB protein activation leads to its nuclear localization, where it then activates the transcription of a number of pro-survival molecules, including Bcl-2, Bcl-xL and various caspase inhibitors. 59 The importance of these transcription factors in CML has been highlighted by evidence that NF-kB is activated in transgenic models of CML 47 and that BCR-ABL can activate NF-kB. 60, 61 Notably, autocrine production of osteopontin, a key component of the HSC niche and regulator of HSC proliferation, results in degradation of the inhibitor of NF-kB, IkB, in BCR-ABL þ cells. [62] [63] [64] The ramifications of BCR-ABL-driven elevation of osteopontin levels detectable in the serum of patients with CML have not been fully investigated. Recent research indicates that osteopontin-expressing osteolineage niche cells initiate HSC mobilization [65] [66] [67] [68] in mouse models. Thus, overexpression of osteopontin in human MPDs may result in MPD HSC mobilization and may enhance quiescent MPD HSC survival at extramedullary sites (Figure 1) .
Finally, FoxO transcription factors are targeted for proteolysis through Akt-mediated signaling. These factors normally induce the transcription of pro-death molecules, including Bim and FasL. In CML, BCR-ABL causes constitutive repression of FoxO3a by continued activation of Akt, 69, 70 leading to yet another mechanism of BCR-ABL-mediated apoptosis resistance. Finally, Akt inhibits GSK3b activity. Thus, the Akt pathway broadly modulates apoptosis and, through regulation of GSK3b, is perhaps intrinsically linked to the Wnt pathway in the deregulation of apoptosis in CML. Although many survival pathways are activated in CML, they are also required by normal stem cells. Thus, elucidation of the hematopoietic developmental stage of survival gene expression will be critical for devising therapies that effectively eradicate CML stem cells while sparing normal stem cells.
CML stem cell therapy
Although allogeneic hematopoietic cell transplantation is the only known curative therapy for CML, transplant-related morbidity from graft-versus-host disease and mortality rates of 10-20% have greatly reduced its use since the advent of molecularly targeted therapy. The relative dearth of toxicity with BCR-ABL-targeted inhibitors, such as imatinib, and prolonged responses observed in chronic phase patients have significantly decreased morbidity and mortality rates associated with CML. 18 Although a hematologic response is observed in over 95% of Figure 1 Upper panel: During normal hematopoiesis, osteopontin-expressing osteoblasts regulate the quiescent hematopoietic stem cell (HSC) pool size as well as HSC mobilization. As HSCs leave the niche, they undergo asymmetric division and differentiate leading to migration of their progeny into the peripheral blood. Lower panel: In myeloproliferative disorders (MPDs), there is an increase in osteoprotegerin production combined with autocrine production of osteopontin by MPD stem cells that may increase stem cell mobilization and HSC survival at extramedullary sites. Conceivably, these mobilized miscreant MPD stem cells could return to subvert the marrow microenvironment by enhancing osteoblast proliferation and amplifying the number of available bone marrow stem cell niches. Niche amplification could sustain quiescent MPD HSC differentiation, survival and self-renewal rendering these miscreant MPD stem cells impervious to therapies that target actively dividing cells. patients in chronic phase, the major molecular responses defined by a three-log decline of the BCR-ABL transcript, detected by reverse-transcriptase (RT)-PCR, have been achieved in less than 5% of patients. 17, 18 Patients in advanced phases of disease initially respond to single-agent tyrosine kinase inhibitor, but inevitably relapse with treatment-refractory disease. 18 This has provided the impetus for understanding the events that fuel progression.
SPOTLIGHT
The precise sequence of molecular events leading to BCR-ABL inhibitor therapeutic recalcitrance, as well as the cellular framework in which they occur, has not been completely elucidated. With our increasing ability to enrich for leukemia stem cells, it should be possible to assess the diagnostic, prognostic and therapeutic relevance of the epigenetic and genetic mechanisms driving leukemia stem cell self-renewal, survival and aberrant differentiation prospectively in the context of clinical trials. Accumulating evidence regarding the cell-typeand context-specific effects of mutations responsible for therapeutic resistance and disease progression suggests that combined therapy targeting the skewed proliferation, survival, differentiation and self-renewal of CML stem and progenitor cells will need to be implemented in patients who do not sustain a molecular remission within a year of starting targeted BCR-ABL inhibitor therapy or who are diagnosed with advanced phase disease at presentation. Clinical trials involving highly active anti-leukemia stem cell therapy combining BCR-ABL inhibition and self-renewal pathway inhibitors with or without additional survival pathway antagonists may eradicate the leukemia stem cell population that represents a reservoir for relapse and prevent progression to blast crisis.
BCR-ABL-negative MPD stem cells
Until recently, very little was known about the molecular pathogenesis of BCR-ABL-negative MPDs. In 2005, seminal studies provided critical insight into the molecular events involved in the development of BCR-ABL-negative MPDs by identifying a mutation (V617F) that constitutively activates the JAK2 tyrosine kinase in the majority of patients with PV and approximately 50% of patients with ET and MF. [71] [72] [73] [74] These reports revealed a point mutation in the JH2 domain resulting in constitutive JAK2 activation. [71] [72] [73] [74] Notably, expression of the JAK2V617F mutant gene recapitulated aspects of PV in the Ba/F3 growth factor-dependent cell line such as erythropoietin (EPO) hypersensitivity and growth factor-independent survival. 73 Moreover, transplantation of mouse marrow cells transduced with the JAK2V617F mutant allele into lethally irradiated recipients resulted in erythrocytosis typical of PV. 73 In addition, mice transplanted with JAK2V617F-expressing cells developed a PVlike disease that progressed to myelofibrosis in a manner analogous to human PV. 75 Then, the JAK2617F mutation was found to be expressed at the HSC level in PV patients and skewed differentiation toward the erythroid lineage. 22, 23 A JAK2 exon 12 mutation and c-mpl, MPLW515L/K, gene mutation were recently described in MPDs, but they are rare in comparison to JAK2V617F. [76] [77] [78] Although JAK2 activation appears to be central to the pathogenesis of BCR-ABL-negative MPDs, emerging evidence indicates that the consequences of JAK2 activation may be cell type and context specific.
BCR-ABL-negative MPD stem cell differentiation
A consideration of the role of JAK2 during distinct phases of both normal and malignant hematopoietic development may shed light on the potential impact of JAK2 inactivation in BCR-ABLnegative MPDs and other JAK2-associated disorders. When first discovered in 1989, through a PCR-based screening strategy, JAK, a non-receptor protein tyrosine kinase, was believed to represent 'just another kinase'. 64 However, JAKs, were later renamed janus kinases, after the two-faced roman god Janus, to reflect their divergent but important roles in mediating intracellular responses to cytokine signaling. Mammalian JAK members include JAK1, 2, 3 and TYK2. 79, 80 These JAKs share a JH2 (kinase-like domain) that plays a critical role in regulating tyrosine kinase activity mediated by the JH1 domain. Although JAK3 mediates signaling through cytokine receptors that utilize the common gamma chain of the IL-2 receptor such as IL-4 and IL-7 and thus regulates adaptive immune responses, JAK2 associates with a multiplicity of cytokine receptors involved in hematopoietic cell growth and differentiation such as the EPO receptor, thrombopoietin (TPO) receptor, granulocyte colonystimulating factor receptor and IL-3.
79,80 JAK2 plays a critical role in mediating hematopoietic stem and progenitor cell-fate decisions. 79, 80 JAK2-mediated transduction of TPO receptor (c-mpl) signaling is critical for stem cell differentiation as well as for megakaryocyte development. JAK2 also regulates EPO receptor signaling, thereby controlling the rate of progenitor differentiation into red blood cells. 79, 80 The role of JAK2 activation in MPD stem cells remains a subject of intense investigation. Earlier, FACS analysis of early-phase PV patient samples revealed an expansion in the number of peripheral blood cells with a HSC phenotype
. 23 In hematopoietic progenitor assays, PV HSC gave rise to a preponderance of large erythroid colonies that expressed the JAK2V617F mutation. 23 These results suggested that the JAK2V617F mutation had an inherent capacity to skew differentiation of PV HSC toward an erythroid fate and enhance their mobilization. 23 However, the molecular mechanisms mediating JAK2V617F human progenitor cell-fate decisions were not elucidated. 23 Recent research demonstrated that enforced expression of JAK2V617F in human HSC and myeloid progenitors skewed differentiation toward the erythroid lineage. 22 This was accompanied by increased expression of GATA-1, an erythroid transcription factor, and decreased expression of PU.1, a myeloid transcription factor, in both PV patient stem cells and JAK2V617F-transduced cord blood progenitor cells. 22 Enforced expression of JAK2V617F in primitive human hematopoietic progenitors resulted in a propensity for erythroid differentiation both in vitro and in a bioluminescent xenogeneic stem cell transplantation model mirroring results obtained with human PV HSC in the same systems. 22 The erythroid differentiation potential of these JAK2V617F expressing human hematopoietic progenitors was inhibited by nanomolar quantities of a selective small molecule ATP-competitive JAK2 inhibitor. 22, 81 Notably, oral administration of this selective JAK2 inhibitor, TG101348, also blocked myeloproliferation and myelofibrosis in a mouse JAK2V617F MPD model. 82 Moreover, TG101348 was found to inhibit JAK2-driven STAT5 phosphorylation and Akt-mediated GATA-1 S310 phosphorylation as well as normalize GATA-1 and PU.1 transcription factor ratios known to regulate hematopoietic progenitor cell-fate decisions, thereby reinstating the full differentiation potential of HSC in PV. 22 Recent evidence suggests that JAK2V617F is expressed by MPD stem cells. 22, 23 However, how one mutation diverts stem cells in PV toward the erythroid lineage and ET to the megakaryocytic lineage remains a major focus of scientific inquiry. This cell-fate determination bias may be due, in part, to the deregulation of the delicate balance of transcription factors.
SPOTLIGHT
For example, in PV stem cells, PCR analysis reveals upregulation of GATA-1 and the downregulation of PU.1 and FOG-1, a megakaryocytic transcription factor. 22 In addition, c-Myb, a transcription factor that is downregulated during megakaryopoiesis, is upregulated in JAK2V617F-transduced CD34 þ cells. Implicated in the erythroid-megakaryocyte bifurcation, c-Myb could be a key factor in cell-fate determination. MicroRNAs, such as miR-150, were recently shown to regulate c-Myb expression, at both the mRNA and protein levels. 83 MicroRNAs are small non-coding RNAs that regulate gene expression and have been implicated in growth and development, cancer and other diseases, as well as cell-fate determination. Whether or not c-Myb expression in JAK2-transduced cells is a result of downregulation of miR-150, and other miRs that target c-Myb (that is, miR-155) is a subject of active investigation. Intensive research efforts are also focusing on whether other miRs are upregulated by JAK2V617F. Some candidate miRs include those targeting the myeloid and megakaryocyte transcription factors, PU.1 and FOG-1. Regulation of JAK2V617F expression levels by specific miRs at different stages of hematopoietic development may explain the dosage effect of the JAK2V617F allele, which contributes to different diseasesFPV, ET and idiopathic myelofibrosis. 84, 85 Recent studies underscored the complexity of miR regulation in JAK2V617F
þ MPD by demonstrating that JAK2V17F mutant allele frequency correlated with miR-143 and was inversely correlated with miR-150. 84, 85 It would be interesting to investigate whether these different MPDs are a result of subtle differential regulation of miRs. Hence, in addition to investigating the miR signature of the JAK2V617F allele that causes the MPDs, unique miR signatures of PV, ET and idiopathic myelofibrosis HSC could reveal mechanistically how a single JAK2V617F allele may have pleiotropic effects. Several miRs have been implicated in development and cancer, and it is possible that JAK2V617F perturbs this delicate balance of gene regulation by altering miR expression, the magnitude of which corresponds to JAK2V617F expression levels. Studies are currently underway to transduce human ES cells with JAK2V617F to determine whether it leads to perturbations in cell-fate determination. Notably, a higher JAK2V617F mutant allele ratio also appears to be associated with erythrocytosis more frequently than thrombocytosis, suggesting that higher expression of this point mutation may induce lineage priming of stem cells toward the erythroid instead of megakaryocytic cell fate. 22, 23 Interestingly, two mutationsFJAK2V617F and MPL515L have been found in the same patient. 76 However, JAK2V617F and JAK2 exon 12 mutations do not seem to coincide. 76, 77 The JAK2 exon 12 mutation is associated with more profound erythrocytosis but its impact on stem cell and progenitor cell-fate decisions compared with JAK2V617F remain to be determined. 77 The disparities between ET and PV may not only relate to HSC commitment but also to differences in late amplification where the JAK2V617VF mutation triggers EPO hypersensitivity and terminal erythroid amplification in primary cells from patients with PV. 86, 87 It is also conceivable that Mpl, EPO-R and G-CSF-R have different sensitivities to JAK2V617F. In addition, expression of JAK2V617F by HSC does not seem to confer a robust advantage over wild-type HSC. 88, 89 These observations indicate that an additional event may precede JAK2V617F and may modify HSC biology to allow for clonal amplification. [90] [91] [92] [93] Results from both mouse JAK2V617F þ bone marrow transplantation models and human JAK2V617F þ progenitor xenogeneic transplantation models indicate that JAK2V617F can initiate the skewed differentiation typical of PV but the events leading to the acquisition of this and other point mutations at the stem cell level are not clear at present. Molecular mutations that induce ET and MF in the 50% of patients who lack the JAK2V617F remain a subject of intensive investigation. There appears to be a cohort of relatively young women with ET. One could speculate that estrogen or another factor such as NFE2 may induce lineage priming of stem cells and alter GATA-1 or FOG-1 resulting in an increased propensity of JAK2V617F to skew differentiation. Moreover, the genetic and epigenetic events involved in progression to AML, although a relatively rare event, have not been completely elucidated. Recent data indicate that AML blasts lack JAK2V617F expression but the stem and progenitor populations remain to be analyzed. 92 In summary, although much has been learned about a central initiating mutation, JAK2V617F, for a large proportion of BCR-ABL-negative MPDs, many questions remain regarding the nature of additional mechanisms driving aberrant stem cell differentiation.
BCR-ABL-negative MPD stem and progenitor cell self-renewal
A large proportion of BCR-ABL-negative MPDs harbor activating mutations in JAK2. [71] [72] [73] [74] In addition to mediating cytokine signaling through a number of cytokine receptors, JAK2 transduces signals from the TPO receptor on binding of TPO, an essential growth factor for stem cells as well as megakaryocytes. 79, 80, 94, 95 Indeed, TPO receptor (mpl) knockout mice have aberrant hematopoiesis, indicating that TPO plays a vital role in HSC function. Mice bearing a truncated TPO receptor (delta 60), which lacks the three major signaling tyrosines in the cytoplasmic tail but retains the JAK2 activation domains (Box 1 and Box 2), have a significant reduction in TPO activation of STAT3 and STAT5 signaling as well as Akt and MAPK signaling. Although TPO receptor (delta 60) mice have a slight defect in long-term HSC (LT-HSC) maintenance, LT-HSCs retain serial transplantation potential in at least two serial transplants, suggesting that JAK2 may be involved in HSC self-renewal and possibly induction of quiescence, through TPO-mediated effects on p57 and p19, which enhances transplantation potential. 96 In JAK2À/À fetal mouse livers, constitutive expression of a STAT5a mutant rescues the defect in HSC maintenance. 97 These experiments have provided the impetus for examining whether or not JAK2 plays a role in human stem cell maintenance. Because of increased availability of more highly immunocompromised mice together with advances in lentiviral technology and non-invasive in vivo imaging, this can now be tested in xenogeneic transplantation models with JAK2-lentivirally transduced human HSC and embryonic stem (hES) cells to determine developmental stage at which stem cells are most susceptible to instructive cues from JAK2.
BCR-ABL-negative MPD survival
Previous studies demonstrated enhanced survival of PV erythroblasts and linked this survival to increased Bcl-xL and FLIP expression through prevention of apoptosis. More recent research suggests that expression of JAK2V617F induces expression of an antiapoptotic protein, Bcl-xL, thereby blocking apoptosis and enhancing survival of JAK2V617F-expressing cells. 98 A recent report suggested that human telomerase reverse transcriptase (hTERT) known to be involved in regulating telomere length, genomic stability and cell survival may also play a role in EPO-induced red blood cell production. 99 EPO was shown to activate hTERT gene expression through a JAK2/STAT5/c-myc axis. 99 This paper suggests that enhanced SPOTLIGHT JAK2 activation may activate hTERT expression and thereby, enhance survival and increase erythroid differentiation of stem cells. 99 Finally, MPD progression to myelofibrosis appears to be associated with an increase in JAK2V617F-expressing HSC 90 as well as overproduction of osteoprotegerin (OPG), which is an essential mediator of osteoblast production. 100 Osteoblasts form an essential component of the HSC niche in the bone marrow microenvironment and thus, increased osteoblast production may enhance the survival of miscreant MPD stem cells returning to the marrow (Figure 1) . Eventually, however, sustained OPG production results in osteosclerosis and an inhospitable environment for stem cells that are dependent on the niche. Therefore, a clone of progenitors that is independent of the niche as a result of aberrant differentiation, survival and selfrenewal potential may become the predominant clone. Conceivably, this miscreant MPD clone would no longer be susceptible to niche-derived negative regulatory signals, such as osteopontin and TGFb, resulting in unfettered clonal expansion and leukemic transformation.
BCR-ABL-negative MPD stem cell therapy
Although JAK2-driven MPDs such as PV, ET and MF have a combined incidence that is fivefold higher than CML, the first leukemia to be associated with a pathognomic molecular abnormality at the HSC level and the first cancer to be treated with molecularly targeted therapy, there has been a relative dearth of therapies that selectively inhibit JAK2 kinase activity. 22, 76, 78, 82 Although JAK2V617F þ PV and ET have a lower rate of progression to acute leukemia than CML, both quality and quantity of life are detrimentally affected by a high prevalence of major thrombotic events. In addition, primary myelofibrosis and AML or myelofibrosis that develops following sustained myeloproliferation in JAK2V617F þ PV or ET are relatively recalcitrant to conventional treatment, thereby providing the rationale for developing selective JAK2 inhibitors. Increased morbidity and mortality rates associated with JAK2-driven MPDs have provided the impetus for developing small molecule JAK2 inhibitors. Moreover, JAK2
þ MPDs represent an important paradigm for understanding the molecular underpinnings of hematopoietic progenitor cell-fate decisions. A number of JAK2 inhibitors have been developed for use in clinical trials including XL019 (Exelixis, South San Francisco, USA), AZD1480 (AstraZeneca, Wilmington, Delaware, USA), INCB018424 (Incyte, Wilmington, Delaware, USA), TG101348 (TargeGen, San Diego, CA, USA), lestaurtinib (CEP701; Cephalon, Frazer, Pennsylvania, USA) erlotinib (Genentech, South San Francisco, USA) and MK-0457 (Merck, Whitehouse Station, New Jersey, USA). 22, 82, 81, [127] [128] [129] [130] Phase 1/ll clinical trials are underway to assess the efficacy of TG101348, XL019 and INCBO18242 in JAK2-driven MPDs, which have a relatively poor prognosis such as myelofibrosis. Preliminary results from the phase 1/ll study suggest that selective JAK2 inhibitors may induce rapid reduction in splenomegaly and that the JAK2V617F mutant allele burdens may decrease. When the safety of these agents is ascertained, trials may be extended to include patients with JAK2-driven PV and ET. Because of the plethora of JAK2 inhibitors currently under development or already in clinical trials, it may be possible to redirect miscreant MPD stem cells and prevent thrombosis, progression to myelofibrosis or transformation to acute leukemia and thereby prevent them from taking precedence over patients diagnosed with MPDs.
'ynever by my will, shall miscreants take precedencey' Antigone by Sophocles.
